Literature DB >> 20678860

Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status.

Junqiang Tian1, Donna M Peehl, Wengwei Zheng, Susan J Knox.   

Abstract

A novel iron chelator, HDp44mT, has been reported to have potent anti-proliferative effects on cancer cells; however, the underlying mechanism of action is not well understood. In this study, we characterized the cytotoxic effect of HDp44mT in a chemo- and radio-resistant cell line (PC-3) of prostatic cancer origin. The activity of HDp44mT at nM concentrations was dependent on the intracellular GSH and atmospheric O(2) concentration, rather than iron deprivation. HDp44mT also radiosensitized PC-3 cells in a GSH-dependent manner. Interestingly, this radiosensitizing effect was observed under aerobic and, to a larger extent, hypoxic conditions, suggesting its potential utility as a radiosensitizer for some radioresistant tumors.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20678860     DOI: 10.1016/j.canlet.2010.07.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.

Authors:  Anne-Marie Charpentier; Debra L Friedman; Suzanne Wolden; Cindy Schwartz; Bethany Gill; Jenna Sykes; Alisha Albert-Green; Kara M Kelly; Louis S Constine; David C Hodgson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-12-01       Impact factor: 7.038

Review 2.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

3.  Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer.

Authors:  G S Coombs; A A Schmitt; C A Canning; A Alok; I C C Low; N Banerjee; S Kaur; V Utomo; C M Jones; S Pervaiz; E J Toone; D M Virshup
Journal:  Oncogene       Date:  2011-06-13       Impact factor: 9.867

4.  A three-in-one-bullet for oesophageal cancer: replication fork collapse, spindle attachment failure and enhanced radiosensitivity generated by a ruthenium(ii) metallo-intercalator.

Authors:  Martin R Gill; Paul J Jarman; Swagata Halder; Michael G Walker; Hiwa K Saeed; Jim A Thomas; Carl Smythe; Kristijan Ramadan; Katherine A Vallis
Journal:  Chem Sci       Date:  2017-11-16       Impact factor: 9.969

Review 5.  Iron Metabolism in Prostate Cancer; From Basic Science to New Therapeutic Strategies.

Authors:  Driton Vela
Journal:  Front Oncol       Date:  2018-11-27       Impact factor: 6.244

6.  Novel iron chelator SK4 demonstrates cytotoxicity in a range of tumour derived cell lines.

Authors:  Gina Abdelaal; Andrew Carter; Mihalis I Panayiotides; David Tetard; Stephany Veuger
Journal:  Front Mol Biosci       Date:  2022-09-23

Review 7.  Targeting iron metabolism in cancer therapy.

Authors:  Michael Morales; Xiang Xue
Journal:  Theranostics       Date:  2021-07-25       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.